Comments
Drug-maker GlaxoSmithKline Pharmaceuticals said that its growth of the core pharmaceuticals business suffered on account of supply chain constraints in parts of its Nashik facility as well as some contract manufacturer sites.
“Growth was also impacted on account of supply constraints around vaccines. The local supply situation is expected to normalise by the end of the second quarter,” Hasit B. Joshipura, Managing Director of the company said, adding that sales on an aggregate basis grew by 1.5 per cent.
The company posted a net profit of Rs 169 crore for its first quarter ended March 31 compared to Rs 122 crore in the corresponding period last quarter, a growth of about 38 per cent.
Total income increased from Rs 703 crore for the quarter ended March 31, 2012 to Rs 713 crore.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.